| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
| ln Vitro |
NecroX-7 (0–40 μM, 3–4 days) suppresses T cells that are active or dividing without resulting in cell death [1]. In a dose-dependent manner, NecroX-7 (0-40 μM) dramatically lowers HMGB1 levels [1]. NecroX-7 prevents tert-butyl hydroperoxide or doxorubicin-induced production of mitochondria-specific reactive nitrogen species (ROS) in H9C2 cells and hepatocytes [1]. The increase in regulatory T cells caused by necroX-7 may be connected to the control of differentiation signals that occurs independently of HMGB1 [1].
|
|---|---|
| ln Vivo |
NecroX-7 (0-0.3 mg/kg, intravenously, every 2 days for 2 weeks) inhibits severe tissue damage and dramatically lowers mortality related to GVHD [1]. NecroX-7 protects mice from fatal GVHD through mutual regulation of regulatory T/Th1 cells, attenuating systemic HMGB1 accumulation and inhibiting HMGB1-mediated inflammatory responses [1].
|
| Cell Assay |
Cell Proliferation Assay[1]
Cell Types: CD4 T Cell Tested Concentrations: 0, 0.625, 1.25, 2.5, 5, 10, 20 and 40 μM Incubation Duration: 3-4 days Experimental Results: demonstrated significant reduction in splenocyte proliferation in a dose-dependent manner sexual manner. Modulates alloreactive T cell responses. |
| Animal Protocol |
Animal/Disease Models: Female BALB/c and C57BL/6 mice (8 weeks old, with GVHD) [1]
Doses: 0.03, 0.1 and 0.3 mg/kg Route of Administration: intravenous (iv) (iv)injection, once every 2 days, continuously Secondary Experimental Results: At doses ≥0.1 mg/kg, statistically significant prolongation of survival was observed: 30-60% of mice in these treatment groups survived beyond 50 days. Clinical symptoms were Dramatically improved, survival time was prolonged, and mice had diminished clinical manifestations of acute GVHD, including weight loss, hunched posture, diarrhea, and fur ruffles. |
| References |
| Molecular Formula |
C24H29N3O3S
|
|---|---|
| Molecular Weight |
439.570364713669
|
| Exact Mass |
439.192
|
| CAS # |
1120332-55-9
|
| PubChem CID |
44187164
|
| Appearance |
Off-white to yellow solid powder
|
| LogP |
3.1
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
31
|
| Complexity |
671
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N1C2=C(C=C(CN3CCS(=O)(=O)CC3)C=C2NC2CCOCC2)C=C1C1=CC=CC=C1
|
| InChi Key |
UZRCNCPUOFYHRB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H29N3O3S/c28-31(29)12-8-27(9-13-31)17-18-14-20-16-22(19-4-2-1-3-5-19)26-24(20)23(15-18)25-21-6-10-30-11-7-21/h1-5,14-16,21,25-26H,6-13,17H2
|
| Chemical Name |
5-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]-N-(oxan-4-yl)-2-phenyl-1H-indol-7-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~227.50 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.69 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.69 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.69 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2750 mL | 11.3748 mL | 22.7495 mL | |
| 5 mM | 0.4550 mL | 2.2750 mL | 4.5499 mL | |
| 10 mM | 0.2275 mL | 1.1375 mL | 2.2750 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
